Overview

Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters

Status:
Not yet recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the full trial is to determine the efficacy and safety of prophylactic dose rivaroxaban to prevent VTE among cancer patients with CVC.
Phase:
Phase 3
Details
Lead Sponsor:
Ottawa Hospital Research Institute
Treatments:
Rivaroxaban